Brokerages Set Radius Health Inc (NASDAQ:RDUS) Price Target at $34.50
Radius Health Inc (NASDAQ:RDUS) has been assigned a consensus recommendation of “Hold” from the ten brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $34.50.
Several analysts have recently weighed in on RDUS shares. Royal Bank of Canada set a $27.00 price objective on Radius Health and gave the company a “hold” rating in a report on Friday, November 1st. BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a report on Friday, January 3rd. HC Wainwright restated a “hold” rating on shares of Radius Health in a report on Friday, December 20th. Leerink Swann cut their price objective on Radius Health from $49.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, ValuEngine upgraded Radius Health from a “sell” rating to a “hold” rating in a report on Friday, January 24th.
Shares of Radius Health stock traded up $0.21 during trading on Friday, hitting $19.97. The stock had a trading volume of 281,268 shares, compared to its average volume of 543,712. The firm has a market cap of $914.21 million, a P/E ratio of -6.13 and a beta of 0.89. The business has a fifty day moving average of $19.43 and a two-hundred day moving average of $23.45. Radius Health has a fifty-two week low of $17.36 and a fifty-two week high of $29.97.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Recommended Story: Mutual Funds
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.